HCV intergenotype 2k/1b recombinant detected in a DAA-treated patient in Italy

Research output: Contribution to journalArticlepeer-review

Abstract

Direct-acting antiviral (DAA) combinations are potent and effective drugs currently recommended for treatment of chronic HCV infection. Difficult to treat genotypes are the most important predictors of treatment failure. We report a case of DAA treatment failure in an HCV-infected patient carrying a recombinant genotype 2k/1b. This strain, first isolated from a Russian patient in 2002, has now been observed for the first time in Italy.

Original languageEnglish
Pages (from-to)365-368
Number of pages4
JournalAntiviral Therapy
Volume22
Issue number4
DOIs
Publication statusPublished - Jan 1 2017

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'HCV intergenotype 2k/1b recombinant detected in a DAA-treated patient in Italy'. Together they form a unique fingerprint.

Cite this